Novavax EV/EBIT NVAX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2025.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 31.2×; Jul 2026
Peer median: 17.8×

Novavax has no meaningful EV/EBIT today: it made an operating loss of $234.1M over the last twelve months.

It was last meaningful in Jul 2026, at 31.2×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	31.2×	1.4×	57.8×
2025	1.5×	1.1×	3.3×

Against its peers

Companies in Biotechnology nearest Novavax's size, closest first, today.

Company	EV/EBIT
NVAXNovavax	n/m
VCELVericel	116×
ADMAAdma Biologics	10.9×
MGTXMeiraGTx	4.6×
KRYSKrystal Biotech	42.4×
RGENRepligen	160×
TECHBIO-TECHNE	44.9×
PLXProtalix BioTherapeutics	7.5×
HALOHalozyme Therapeutics	17.4×
NBIXNeurocrine Biosciences	18.2×
EXELExelixis	15.4×
Peer median	17.8×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Novavax

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.